Evaluating Mitozolomide for Ovarian Cancer
Author Information
Author(s): M. Harding, D. Northcott, J. Smyth, N.S.A. Stuart, J.A. Green, E. Newlands
Primary Institution: Gartnavel General Hospital, Glasgow
Hypothesis
Does mitozolomide have activity in patients with epithelial ovarian tumors?
Conclusion
Mitozolomide appears to have no useful activity in patients with extensively pretreated epithelial ovarian cancer.
Supporting Evidence
- Ten patients (50%) experienced no gastrointestinal toxicity.
- Two patients died within 28 days of entry and are excluded from the results.
- Significant thrombocytopenia occurred in 3 of 9 patients receiving 90 mg/m².
Takeaway
This study tested a new drug called mitozolomide on women with ovarian cancer, but it didn't help them get better.
Methodology
Patients received either 70 mg/m² or 90 mg/m² of mitozolomide, and their responses were evaluated based on standard criteria.
Limitations
Most patients were extensively pretreated, which may have affected the results.
Participant Demographics
Patients had a median age of 53 to 64 years and varied performance status.
Want to read the original?
Access the complete publication on the publisher's website